Clinical Trial Search

Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…

Primary: Interviews — 20 Interviews

Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025

Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg

Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001

Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD

Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)

Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants

Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT

Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants

Primary: Percent Change in D-dimer Value — 9.9; -21.9 percent change — p=0.92

Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance

Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants

Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…

Primary: Objective Response Rate — 0; 1 participants

Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…

Primary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Clinical Tumor Regression — 1 Participants

Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Confirmed Objective Response Rate (cORR) by RECISTv1.1 — 40 percentage of participants

Primary: Mean Changes From Baseline in Self-esteem Scores on the Rosenberg Self-esteem Scale (RSES) to Two-, Six-, and Eight Weeks Post Baseline — 23.4; 23.5; 23.7; 24.2 score on…

Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)

Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months

Primary: Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status — 380.2; 421.9; 308.0; 281.9 Incidence per 100,000 person-years

Primary: Maximum T Cell Response From Baseline — 10.5; 51.75; 270.625 spots per 10^4 CD8+ cells — p=0.028